Phase 2 N=20 Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Recurrent Pleural Malignant Mesothelioma · Stage IV Pleural Mesothelioma
Primary: Progression-free Survival (PFS) — 1.8 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=400 NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Malignant Pleural Mesothelioma
Primary: Overall Survival (OS) — 8.5; 8.0 months — p=0.58
Phase 2 N=34 Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
Advanced Malignant Mesothelioma · Localized Malignant Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST) — 47.8 percentage of…
Phase 2 N=32 Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Mesothelioma
Primary: Best Overall Response by RECIST Criteria (Version 1.0) — 3; 0; 7; 6 eligible, treated participants
Phase 2 N=77 Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
Pleural Neoplasms
Primary: Pathological Complete Response — 3 participants
Phase 3 N=53 Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
Primary: Overall Survival — 17.6; 15.5 Months — p=0.2840
Phase 3 N=72 Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
Malignant Pleural Effusion
Primary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants
Phase 2 N=34 Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Malignant Pleural Mesothelioma · Mesothelioma
Primary: Disease Control Rate (DCR) — 75 percentage of participants
Phase 2 N=39 Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
Advanced Malignant Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Objective Response (Partial and Complete) Per RECIST — 1 participants
Phase 2 N=248 Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Mesothelioma
Primary: Progression-free Survival (PFS), [95% CI] — 4.3; 4.5 months — p=0.859125
Phase 2 N=24 MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Mesothelioma
Primary: Change in Ratio of Intratumoral Cytotoxic T Cells to Regulatory T Cells (CD8/Treg) — 8.6 no unit of ratios with same units(%) — p=0.109
Phase 3 N=144 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma
Pleural Mesothelioma Malignant Advanced
Primary: Progression Free Survival (PFS) as Assessed by Independent Radiological Review — 2.5; 3.4 months — p=0.76
Phase 2 N=53 Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Mesothelioma
Primary: Progression Free Survival Rate at 6 Months — 56 percentage of participants
Phase 2 N=45 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
Mesothelioma · Adenocarcinoma of Lung · Pancreatic Neoplasms
Primary: Response Assessment — 0; 0; 0; 0 Participants
Phase 2 N=53 Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Malignant Mesothelioma
Primary: Progression-free Survival — 3.0; 3.4 months
Phase 2 N=14 Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
Pleural Malignant Mesothelioma
Primary: 3-month Progression Free Survival Rate — 3 Participants
Phase 1 N=24 Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
Pleural Malignant Mesothelioma
Primary: Safety/Toxicity — 0; 0 participants
Phase 2 N=26 Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Lung Cancer · Mesothelioma
Primary: Disease Control Rate at 4 Months — 8 Participants
Phase 3 N=520 Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Mesothelioma
Primary: Phase II: Progression Free Survival Measured as Time From Randomization to First Observation of Objective Disease Relapse or Progression — 6.7; 6.8; 5.26 months
Phase 2 N=61 S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Malignant Mesothelioma
Primary: Progression-Free Survival — 3.0 months
Phase 2 N=65 Pembrolizumab in Treating Patients With Malignant Mesothelioma
Biphasic Mesothelioma · Epithelioid Mesothelioma · Peritoneal Malignant Mesothelioma
Primary: Ability of PD-L1 to Predict Response — 0.377 Youden index
N/A N=119 Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter
Malignant Pleural Effusion
Primary: The Proportion of Subjects Achieving Pleurodesis Without Recurrence. — 17; 12 Participants
Phase 2 N=47 Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma
Mesothelioma; Lung
Primary: To Evaluate the Efficacy of the Treatment — 1.9 Months
Phase 2 N=28 A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma · Non-Small Cell Lung Cancer
Primary: Phase 1 Part: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Drug Reactions (ADRs) — 4; 0; 0; 1 Participants
Phase 2 N=54 S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
Advanced Malignant Mesothelioma · Epithelial Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Overall Response Rate — 9 percentage of participants
Phase 2 N=51 Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Advanced Malignant Mesothelioma · Epithelial Mesothelioma · Localized Malignant Mesothelioma
Primary: Objective Response Rate, Complete (CR) or Partial (PR) Response — 5 percentage of participants
Phase 2 N=2 A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
Mesothelioma · Peritoneal Mesothelioma
Primary: Major Pathologic (Disease) Response of Tumor to Nivolumab Combined With Ipilimumab Before Surgery
Phase 2 N=11 Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Malignant Pleural Mesothelioma
Primary: To Determine the Rate of Clinical Benefit (i.e. Rate of Complete or Partial Response Plus Stable Disease) at 16 Weeks for Patients With Malignant Mesothelioma Treated…
Phase 2 N=41 Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Malignant Pleural Mesothelioma
Primary: 1-year Progression-free Survival — 44; 33 percentage of participants
Phase 2 N=13 PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
Advanced Malignant Mesothelioma · Epithelial Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Objective Tumor Response Rate According to the Response Evaluation Criteria in Solid Tumors (RECIST) Committee — 0 percentage of participants